Are you an EPFL student looking for a semester project?
Work with us on data science and visualisation projects, and deploy your project as an app on top of GraphSearch.
Background The pathways that control protein transport across the blood-brain barrier (BBB) remain poorly characterized. Despite great advances in recapitulating the human BBB in vitro, current models are not suitable for systematic analysis of the molecular mechanisms of antibody transport. The gaps in our mechanistic understanding of antibody transcytosis hinder new therapeutic delivery strategy development. Methods We applied a novel bioengineering approach to generate human BBB organoids by the self-assembly of astrocytes, pericytes and brain endothelial cells with unprecedented throughput and reproducibility using micro patterned hydrogels. We designed a semi-automated and scalable imaging assay to measure receptor-mediated transcytosis of antibodies. Finally, we developed a workflow to use CRISPR/Cas9 gene editing in BBB organoid arrays to knock out regulators of endocytosis specifically in brain endothelial cells in order to dissect the molecular mechanisms of receptor-mediated transcytosis. Results BBB organoid arrays allowed the simultaneous growth of more than 3000 homogenous organoids per individual experiment in a highly reproducible manner. BBB organoid arrays showed low permeability to macromolecules and prevented transport of human non-targeting antibodies. In contrast, a monovalent antibody targeting the human transferrin receptor underwent dose- and time-dependent transcytosis in organoids. Using CRISPR/Cas9 gene editing in BBB organoid arrays, we showed that clathrin, but not caveolin, is required for transferrin receptor-dependent transcytosis. Conclusions Human BBB organoid arrays are a robust high-throughput platform that can be used to discover new mechanisms of receptor-mediated antibody transcytosis. The implementation of this platform during early stages of drug discovery can accelerate the development of new brain delivery technologies.
Loading
Loading
Loading
Loading
One of the long-standing goals in the field of tissue engineering is the fabrication of de novo tissues or even organs to provide better tissue models for basic research and drug discovery, and to alleviate a shortage of donor organs in the future. Research in recent decades to understand tissue biology has led to the discovery of stem cell niches and the development of innovative protocols for the generation of three-dimensional in vivo-like tissues called organoids. Organoids represent multiple histological and functional aspects of real organs and offer unprecedented perspectives for modelling tissue development, regeneration, and disease in vitro. However, relying so far almost exclusively on spontaneous self-organisation of stem cells, organoids develop uncontrollably into small structures of highly variable size and architecture. Moreover, the closed, cystic architecture of most epithelial organoids limits their lifespan and makes experimental manipulation difficult. In this thesis, three innovative engineering technologies were developed that offer the possibility of steering in vitro stem cell patterning and organoid formation into more controllable and physiologically relevant miniature tissues. The aim of the first project was to study how predefined geometric constraints, as they exist in vivo, affect organoid development. This required the development of a novel fabrication process of the topographically micro-patterned hydrogel surfaces. This approach allowed the generation of large arrays of the identical organoids, having pre-defined shape and size to study cellular mechanisms involved in the proper, stereotypical cell type pattering of intestinal organoids. The second project focused on replicating tissue dynamics and aspects of organ physiology by developing a novel three-dimensional organ-on-chip approach. Using stem cells derived from patient biopsies, this technology enables to production of miniature versions of patientâs organs that can be used in personalized diagnostics and medical treatment assays. Bioprinting has long been considered as one of the most promising technologies for fabricating organs in vitro. However, despite encouraging advances made in recent years, the degree of multicellular spatial complexity and function of organoids remains unmatched by any existing bioprinting technology. Therefore, the third project was aimed to develop a new bioprinting strategy that preserves local stem cell self-organization potential and extends organoids growth to the macroscopic scale. Overall, this thesis introduces several cutting-edge technologies that offer the possibility to control in vitro organoid development and should therefore become efficient research tools to facilitate the translation of organoid technology towards pharmaceutical and clinical applications. Hydrogel micro-pattering is an efficient technology that can be widely used to explore the mechanisms by which tissue geometry can regulate morphogenesis of different organs and can be readily applied for high-throughput screening in pharmacological assays. The microscope-based bioprinter can be set-up in any laboratory to guide stem cell self-organization and tissue morphogenesis from millimetre to centimetre scales. The microfluidic organoid-on-chip concept should enable the creation of various miniature organs with complex three-dimensional spatial organisation and multicellular complexity for basic research and drug discovery.
Daniel Alpern, Antonio Carlos Alves Meireles Filho, Riccardo Dainese, Bart Deplancke, Vincent Roland Julien Gardeux, Jia Yuan Jiang, Gerard Llimos Aubach